Bragar Eagel & Squire, P.C. has announced the initiation of class action lawsuits against PomDoctor and Vistagen Therapeutics, alleging securities law violations by both companies. PomDoctor faces allegations centered on fraudulent stock promotion practices and insider share dispositions, while Vistagen Therapeutics confronts litigation following a significant equity decline triggered by disappointing clinical trial results.
Vistagen's stock experienced an 80% decline following the failure of its Phase 3 trial for fasedienol to achieve primary efficacy endpoints. The adverse clinical outcome has prompted investor litigation regarding potential disclosure inadequacies preceding the trial announcement. The pharmaceutical company's stock performance reflects the substantial shareholder value destruction resulting from the trial outcome.
Investors holding securities in either company during the relevant periods have limited windows to file claims. Shareholders seeking to serve as lead plaintiffs in the PomDoctor action must petition by April 7, 2026, while those pursuing claims against Vistagen face a March 16, 2026 deadline. The law firm is encouraging affected investors to contact the firm to discuss potential claims and lead plaintiff eligibility.